4554 — Fuji Pharma Co Balance Sheet
0.000.00%
- ¥39bn
- ¥64bn
- ¥46bn
- 83
- 74
- 84
- 95
Annual balance sheet for Fuji Pharma Co, fiscal year end - September 30th, JPY millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 12,041 | 10,199 | 3,546 | 2,324 | 4,585 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 11,708 | 11,984 | 12,661 | 16,520 | 18,879 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 34,975 | 34,834 | 34,727 | 39,114 | 42,468 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 12,767 | 14,392 | 18,762 | 20,547 | 20,911 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 61,962 | 64,239 | 75,538 | 85,332 | 90,000 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11,004 | 20,192 | 23,975 | 29,771 | 35,797 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 22,003 | 31,559 | 39,734 | 44,157 | 44,440 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 39,959 | 32,680 | 35,804 | 41,175 | 45,560 |
| Total Liabilities & Shareholders' Equity | 61,962 | 64,239 | 75,538 | 85,332 | 90,000 |
| Total Common Shares Outstanding |